House Panel Blocks Cannabis Rescheduling Despite Trump Support
GOP-controlled appropriations subcommittee votes to defund federal cannabis rescheduling efforts, creating political friction with Trump administration backing.
The House Appropriations Subcommittee on Commerce, Justice, Science, and Related Agencies approved funding legislation Thursday that includes language blocking federal resources for cannabis rescheduling implementation. The move creates an unusual political dynamic where Republican lawmakers oppose a reform effort that has gained Trump administration support, highlighting the complex congressional dynamics surrounding cannabis policy.
The appropriations rider represents a procedural roadblock rather than an outright policy reversal, but demonstrates the fragmented approach to cannabis reform within Republican ranks. While the provision would prevent agencies from using allocated funds to implement rescheduling, it requires passage through the full House and Senate to take effect. The timing creates uncertainty for cannabis operators who have positioned themselves for federal scheduling changes.
Cannabis equity markets have shown volatility around federal policy developments, with major operators like Curaleaf (CURA), Green Thumb Industries (GTII), and Trulieve (TCNNF) experiencing significant price swings based on rescheduling expectations. The sector trades at compressed valuations compared to traditional consumer goods companies, partly due to federal scheduling restrictions that limit banking access and create tax disadvantages under 280E provisions.
The congressional resistance reflects broader Republican concerns about federal cannabis liberalization, despite growing state-level adoption and industry maturation. Twenty-four states have legalized adult-use cannabis, creating a $30 billion legal market that operates under complex federal-state regulatory tensions. Banking restrictions continue to force cash-heavy operations and limit institutional investment access.
Industry observers view the appropriations battle as part of ongoing federal cannabis policy negotiations rather than a definitive policy shift. The disconnect between congressional Republicans and Trump administration positioning on cannabis creates additional regulatory uncertainty for operators planning expansion strategies and capital allocation decisions in 2024.